Copyright of Natures Sciences Sociétés is the property of EDP Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Australia, Biology, Canada, Culture, Europe, Family Characteristics, Family Relations, Latin America, Population, Sex Distribution, Sex Factors, Social Sciences, United States, Age Factors, Birth Order, Demography, Developed Countries, Ethnicity, Politics, Population Characteristics, Sex Ratio
Adult, Aged, Aged, 80 and over, Biosimilar Pharmaceuticals economics, Canada, Europe, Female, Filgrastim economics, Humans, Male, Middle Aged, Stem Cells physiology, United States, Young Adult, Biosimilar Pharmaceuticals therapeutic use, Clinical Trials as Topic, Filgrastim therapeutic use, Hematopoietic Stem Cell Transplantation adverse effects, Neutropenia drug therapy, Neutropenia etiology, Stem Cells drug effects
Abstract
Originator GCSF (Neupogen) has been used to mobilize progenitor stem cells and treat therapy-induced neutropenia in Canadian stem cell transplant settings for years. Although its benefit is not in question, viable alternatives are available. Biosimilar GCSF (Zarzio) is widely in use in Europe since 2009 and was recently approved in the U.S.for the same five indications as Neupogen. Zarzio is reported as safe, equally efficacious, more accessible and cost effective without negatively impacting patient outcomes. This paper summarizes the supporting evidence.
Published
2015
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.